Evidence map›Paper›PMID 41294574›Full record

ReviewGels (Basel, Switzerland)2025

Hydrogels in the Immune Context: In Vivo Applications for Modulating Immune Responses in Cancer Therapy.

Mara R Lanis, Sujin Kim, Jonathan P Schneck

Abstract readReview
In one paragraph

Review in Gels (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mara R LanisDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21218, USA.ORCID 0000-0002-1620-8733
Sujin KimDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21218, USA.ORCID 0009-0007-7845-4650
Jonathan P SchneckDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21218, USA.

Funding

TR&D Project 3P41EB028239 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI Jamie Berta Spangler · 2019 to 2026
$11.5M
Biomimetic Matrix for Ex Vivo and In Vivo Activation of T CellsR01EB029341 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI MAO, HAI-QUAN, SCHNECK, JONATHAN P · 2020 to 2023
$1.9M
Antigen-specific T cell Redirectors, ATR, for immunotherapyR21CA185819 · NCI · JOHNS HOPKINS UNIVERSITY · PI SCHNECK, JONATHAN P · 2015 to 2016
$388k
CD4+ T Cell Activating Hydrogels for Cancer ImmunotherapyF31CA301836 · NCI · JOHNS HOPKINS UNIVERSITY · PI Mara Rebecca Lanis · 2025 to 2026
$100k
NCI NIH HHS F31 CA301836NCI NIH HHS R21 CA185819NIBIB NIH HHS P41 EB028239NIBIB NIH HHS R01 EB029341NIH HHS 1F31CA301836-01A1NIH HHS P41EB028239NIH HHS R01EB029341NIH HHS R21CA185819
6 · The paper itself

Abstract

In response to growing clinical demands for more targeted and effective immunotherapies to treat cancer, biomaterial-based strategies have emerged as powerful tools for locally regulating immune responses. Among these, hydrogels, a class of biocompatible and tunable polymeric networks, are increasingly being leveraged for their high versatility and adaptability for creating tailored immune environments. By enabling controlled delivery of immune cues and direct cellular engineering, hydrogels utilized in vivo can precisely regulate both innate and adaptive immune responses while minimizing systemic toxicity. In this review, we outline essential hydrogel design features necessary for in vivo functionality including injectability, degradation kinetics, and immune-specific functionalization. Building on these principles, we explore how hydrogels have been employed to enhance T cell activation and dendritic cell maturation and guide macrophage reprogramming. Beyond cellular modulation, we further examine the use of hydrogels for cytokine and immunoregulatory agent delivery, tumor microenvironment remodeling, and the creation of tertiary-like lymphoid structures. Finally, we review recently completed and ongoing clinical trials of hydrogels in the cancer immunotherapy space. Together, these insights underscore the growing potential of in vivo hydrogel systems as immuno-interactive platforms capable of reshaping immune responses across diverse disease contexts.

Indexed as

cancerdendritic cellsdrug releasehydrogelsimmunotherapyin vivomacrophagesT cellstumor microenvironment

Identifiers

PMID41294574
PMCPMC12652042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.